Active, Not Recruiting
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed - CA209-8RX
Actualizada: 7 septiembre, 2021 | ClinicalTrials.gov
Géneros
Rango de edad
Active, Not Recruiting
Inclusion Criteria: - Patients with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection and have no evidence of disease. - Decision to treat with adjuvant nivolumab therapy has already been taken - At least 18 years of age at the time of treatment decision - Patients who provide written informed consent to participate in the study Exclusion Criteria: - Any patient with a current diagnosis of persisting advanced melanoma - Any patient currently enrolled in an interventional clinical trial for his/her melanoma treatment (note: patients who have completed their participation in an interventional trial or who are no longer receiving the study drug and are only followed up for OS/RFS can be enrolled. In case of a blinded study, the treatment arm needs to be known). Other protocol defined inclusion/exclusion criteria could apply
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
